Researchers reported in Science Translational Medicine that highly specific monoclonal antibodies targeting MMP-9 can slow and even reverse diabetic nerve pain in mouse models. The work focuses on matrix metalloproteinase-9 (MMP-9), an enzyme implicated in neuroinflammation that drives diabetic peripheral neuropathy. The team used functional selection to winnow down roughly 1.7 billion antibody fragments toward MMP-9-specific candidates. They contrasted the approach with earlier efforts relying on broad-spectrum MMP inhibition, which have been associated with low efficacy and severe side effects. The study also referenced experiments where combinations of antibodies blocking the inflammatory molecule at the core of neuropathy produced symptom reversal in some animals. The investigators frame the results as a step toward a disease-modifying treatment, where available options have largely targeted pain symptoms rather than underlying pathology. The findings place antibody engineering back in the spotlight for challenging targets where prior small-molecule strategies struggled with selectivity and tolerability.